Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24451143 | 0.93 | POLB (0.45) | POLBMEN1KMT2AEPHX1ALDH1A1 | |
| SCHEMBL24966292 | 0.86 | POLB (0.41) | POLBMEN1KMT2AEPHX1ALDH1A1 | |
| SCHEMBL22650107 | 0.85 | POLB (0.40) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL23888839 | 0.83 | EPHX1 (0.37) | POLBMEN1KMT2AEPHX1TDP1 | |
| SCHEMBL20758283 | 0.83 | POLB (0.36) | POLBMEN1KMT2AEPHX1ALDH1A1 | |
| SCHEMBL14524176 | 0.83 | EPHX2 (0.50) | POLBMEN1KMT2AEPHX1SMN1; SMN2 | |
| SCHEMBL10633351 | 0.82 | MEN1 (0.58) | POLBMEN1KMT2AEPHX1ALDH1A1 | |
| SCHEMBL24451194 | 0.81 | POLB (0.38) | POLBMEN1KMT2AEPHX1ALDH1A1 | |
| SCHEMBL18622113 | 0.80 | POLB (0.57) | POLBMEN1KMT2AEPHX1ALDH1A1 | |
| SCHEMBL25727664 | 0.80 | POLB (0.39) | POLBMEN1KMT2AEPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210300934-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | POLB 2977/4885MEN1 139/4885KMT2A 4577/4885 |
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | POLB 2977/4885MEN1 139/4885KMT2A 4577/4885 |
| US-20210300934-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | POLB 2977/4885MEN1 139/4885KMT2A 4577/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | POLB 3209/4885MEN1 108/4885KMT2A 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.